Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Clinical trial NCT03739814 · RECRUITING

Trial details

NCT number: NCT03739814
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Recurrent B Acute Lymphoblastic Leukemia Refractory B Acute Lymphoblastic Leukemia

Start date: 2019-05-08
Primary completion: 2027-02-01
Enrollment: 84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.